Investor Third Rock Ventures III, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Third Rock Ventures III, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2024-02-14 13G/A VYGR / Voyager Therapeutics, Inc. 5,465,634 186,423
2024-02-14 13G/A FULC / Fulcrum Therapeutics, Inc. 2,343,154 2,343,154
2024-02-14 13G/A PLRX / Pliant Therapeutics, Inc. 2,132,867 2,132,867
2023-02-14 13G/A FULC / Fulcrum Therapeutics, Inc. 4,046,425 2,343,154
2023-02-14 13G/A PLRX / Pliant Therapeutics, Inc. 5,839,160 2,132,867
2023-02-14 13G/A NRIX / Nurix Therapeutics, Inc. 2,550,757 184,544
2023-02-14 13G/A RVMD / Revolution Medicines, Inc. 5,653,290 1,939,692
2023-02-14 13G/A VYGR / Voyager Therapeutics, Inc. 9,419,297 5,465,634
2022-02-14 13G DBTX / Decibel Therapeutics Inc 3,139,685
2022-02-14 13G/A RVMD / Revolution Medicines, Inc. 8,949,069 5,653,290
2022-02-14 13G/A RLAY / Relay Therapeutics, Inc. 10,551,115 362,619
2022-02-14 13G/A NRIX / Nurix Therapeutics, Inc. 5,422,549 2,550,757
2022-02-14 13G/A FULC / Fulcrum Therapeutics, Inc. 5,962,202 4,046,425
2021-02-16 13G NRIX / Nurix Therapeutics, Inc. 5,422,549
2021-02-16 13G PLRX / Pliant Therapeutics, Inc. 5,839,160
2021-02-16 13G RVMD / Revolution Medicines, Inc. 8,949,069
2021-02-16 13G RLAY / Relay Therapeutics, Inc. 10,551,115
2020-02-05 13G FULC / Fulcrum Therapeutics, Inc. 5,962,202
2019-02-13 13G NTGN / Neon Therapeutics, Inc. 9,741,636
2018-02-13 13G/A VYGR / Voyager Therapeutics, Inc. 10,317,067 9,419,297
2018-02-13 13G/A EDIT / Editas Medicine, Inc. 3,912,066 935,634
2017-02-13 13G/A VYGR / Voyager Therapeutics, Inc. 11,061,176 10,317,067
2017-02-13 13G EDIT / Editas Medicine, Inc. 3,912,066
2016-02-10 13G VYGR / Voyager Therapeutics, Inc. 11,061,176